<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="97478">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01939457</url>
  </required_header>
  <id_info>
    <org_study_id>2.2.4</org_study_id>
    <nct_id>NCT01939457</nct_id>
  </id_info>
  <brief_title>400mcg Sublingual Misoprostol as First Line Treatment</brief_title>
  <official_title>Introduction of 400mcg Sublingual Misoprostol as First Line Treatment in 11 Health Posts in Three Districts in Senegal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynuity Health Projects</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gynuity Health Projects</source>
  <oversight_info>
    <authority>Senegal: Local Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Women presenting with incomplete abortion and eligible for treatment with misoprostol were
      offered 400mcg sublingual misoprostol for treatment. Based on existing literature, the study
      hypothesises that women can successfully be treated with misoprostol alone as first line
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>complete abortion</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>number of complete abortion with misoprostol treatment alone</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">641</enrollment>
  <condition>Incomplete Abortion</condition>
  <arm_group>
    <arm_group_label>misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mcg misoprostol sublingually</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <arm_group_label>misoprostol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  uterine size less than 12 weeks lmp

          -  open cervical os

          -  current or past vaginal bleeding

          -  willing to provide contact information for follow-up

          -  over 18 or with guardian consent

        Exclusion Criteria:

          -  suspicion of ectopic pregnancy

          -  intrauterine device in place

          -  bad general health (infection, anemia, shoc)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverly Winikoff, MD MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guediawaye Health Center</name>
      <address>
        <city>Guediawaye</city>
        <country>Senegal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Senegal</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 6, 2013</lastchanged_date>
  <firstreceived_date>August 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Abortion, Incomplete</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
